Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F.
Szmania S, et al. Among authors: rooney c.
J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.
J Immunother. 2015.
PMID: 25415285
Free PMC article.
Clinical Trial.